Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,876 Cr
verified against source
Revenue YoY
11%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Alembic Pharmaceuticals reported Q3 FY26 revenue of ₹2,876 crore, up 11% YoY, driven by volume expansion and new launches, partially offset by US generics and API pricing pressure. PAT before exceptional items grew 21% YoY to ₹168 crore, aided by cost efficiencies. India branded business grew only 6% YoY, below market, with management targeting alignment by Q1 FY27. US business grew 6% YoY, with full-year guidance of 10-12% growth. R&D spend was ₹165 crore (9% of revenue), in line with full-year guidance of ₹600-650 crore. The upcoming launch of branded product Pivya (pivmecillinam) in the US in Q4 is a key strategic shift, though near-term profitability will be impacted. Risks include persistent pricing pressure in US generics and API, and continued underperformance in the domestic market.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects US business to grow 10-12% for the full year FY26, driven by volume growth and new launches.
- Management expects India branded business growth to converge with the market growth rate by Q1 of the next financial year.
- Full-year R&D spend guidance of ₹600-650 crore, representing 8-9% of revenue.
- First branded product Pivya to be launched in the US in Q4 FY26, with prescription share scaling over 12-18 months.
Risks flagged
- Pricing pressure in US generics and API businesses persisted during the quarter, partially offset by cost efficiencies.
- India branded business grew only 6% YoY, below market growth, and management has not provided a clear timeline for improvement beyond Q1 FY27.
- The branded product Pivya launch will impact near-term profitability, with management unable to quantify the margin impact.
- Management expects injectables and complex generics to drive US growth over the next 2-3 years, but approvals and ramp-up remain uncertain.
Key quotes
- We hope to launch another four to five products in the fourth quarter of the year. We also on track to launch our first branded product in the US in February 2026.
- I think Q1 of the coming financial year is where we feel we should be back in line with the market growth rate.
- I think the whole doctor spend scenario in the context of UCMP possibly we were too conservative and extremely sensitive to it relative to the market.
Research modules